206 related articles for article (PubMed ID: 17027571)
1. Relation of improvement in endothelium-dependent flow-mediated vasodilation after rosiglitazone to changes in asymmetric dimethylarginine, endothelin-1, and C-reactive protein in nondiabetic patients with the metabolic syndrome.
Wang TD; Chen WJ; Cheng WC; Lin JW; Chen MF; Lee YT
Am J Cardiol; 2006 Oct; 98(8):1057-62. PubMed ID: 17027571
[TBL] [Abstract][Full Text] [Related]
2. Effects of rosiglitazone on endothelial function, C-reactive protein, and components of the metabolic syndrome in nondiabetic patients with the metabolic syndrome.
Wang TD; Chen WJ; Lin JW; Chen MF; Lee YT
Am J Cardiol; 2004 Feb; 93(3):362-5. PubMed ID: 14759393
[TBL] [Abstract][Full Text] [Related]
3. Effect of rosiglitazone on endothelial function and inflammatory markers in patients with the metabolic syndrome.
Esposito K; Ciotola M; Carleo D; Schisano B; Saccomanno F; Sasso FC; Cozzolino D; Assaloni R; Merante D; Ceriello A; Giugliano D
Diabetes Care; 2006 May; 29(5):1071-6. PubMed ID: 16644639
[TBL] [Abstract][Full Text] [Related]
4. Effects of rosiglitazone on endothelial function in men with coronary artery disease without diabetes mellitus.
Sidhu JS; Cowan D; Kaski JC
Am J Cardiol; 2004 Jul; 94(2):151-6. PubMed ID: 15246889
[TBL] [Abstract][Full Text] [Related]
5. Pharmacodynamic effects of rosiglitazone in nondiabetic patients with metabolic syndrome.
Aquilante CL; Kosmiski LA; Zineh I; Rome LC; Knutsen SD
Pharmacotherapy; 2010 Mar; 30(3):236-47. PubMed ID: 20180607
[TBL] [Abstract][Full Text] [Related]
6. Effects of rosiglitazone on lipids, adipokines, and inflammatory markers in nondiabetic patients with low high-density lipoprotein cholesterol and metabolic syndrome.
Samaha FF; Szapary PO; Iqbal N; Williams MM; Bloedon LT; Kochar A; Wolfe ML; Rader DJ
Arterioscler Thromb Vasc Biol; 2006 Mar; 26(3):624-30. PubMed ID: 16357312
[TBL] [Abstract][Full Text] [Related]
7. Effects of rosiglitazone alone and in combination with atorvastatin on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus.
Chu CS; Lee KT; Lee MY; Su HM; Voon WC; Sheu SH; Lai WT
Am J Cardiol; 2006 Mar; 97(5):646-50. PubMed ID: 16490430
[TBL] [Abstract][Full Text] [Related]
8. Effects of combining simvastatin with rosiglitazone on inflammation, oxidant stress and ambulatory blood pressure in patients with the metabolic syndrome: the SIROCO study.
Lazich I; Sarafidis P; de Guzman E; Patel A; Oliva R; Bakris G
Diabetes Obes Metab; 2012 Feb; 14(2):181-6. PubMed ID: 21955403
[TBL] [Abstract][Full Text] [Related]
9. Effect of rosuvastatin on plasma levels of asymmetric dimethylarginine in patients with hypercholesterolemia.
Lu TM; Ding YA; Leu HB; Yin WH; Sheu WH; Chu KM
Am J Cardiol; 2004 Jul; 94(2):157-61. PubMed ID: 15246890
[TBL] [Abstract][Full Text] [Related]
10. Relationship between protective effects of rosiglitazone on endothelium and endogenous nitric oxide synthase inhibitor in streptozotocin-induced diabetic rats and cultured endothelial cells.
Wang S; Jiang JL; Hu CP; Zhang XJ; Yang DL; Li YJ
Diabetes Metab Res Rev; 2007 Feb; 23(2):157-64. PubMed ID: 16770837
[TBL] [Abstract][Full Text] [Related]
11. Influence of rosiglitazone on flow-mediated dilation and other markers of cardiovascular risk in HIV-infected patients with lipoatrophy.
Kovacic JC; Martin A; Carey D; Wand H; Mallon PW; Feneley MP; Emery S; Cooper DA; Carr A;
Antivir Ther; 2005; 10(1):135-43. PubMed ID: 15751771
[TBL] [Abstract][Full Text] [Related]
12. Effects of rosiglitazone and metformin on inflammatory markers and adipokines: decrease in interleukin-18 is an independent factor for the improvement of homeostasis model assessment-beta in type 2 diabetes mellitus.
Kim HJ; Kang ES; Kim DJ; Kim SH; Ahn CW; Cha BS; Nam M; Chung CH; Lee KW; Nam CM; Lee HC
Clin Endocrinol (Oxf); 2007 Feb; 66(2):282-9. PubMed ID: 17224000
[TBL] [Abstract][Full Text] [Related]
13. Peroxisome proliferator-activated receptor-gamma activation with pioglitazone improves endothelium-dependent dilation in nondiabetic patients with major cardiovascular risk factors.
Campia U; Matuskey LA; Panza JA
Circulation; 2006 Feb; 113(6):867-75. PubMed ID: 16461819
[TBL] [Abstract][Full Text] [Related]
14. The presence of metabolic syndrome is independently associated with elevated serum CD40 ligand and disease severity in patients with symptomatic coronary artery disease.
Lee WL; Lee WJ; Chen YT; Liu TJ; Liang KW; Ting CT; Huey-Herng Sheu W
Metabolism; 2006 Aug; 55(8):1029-34. PubMed ID: 16839837
[TBL] [Abstract][Full Text] [Related]
15. Inflammation, insulin, and endothelial function in overweight children and adolescents: the role of exercise.
Kelly AS; Wetzsteon RJ; Kaiser DR; Steinberger J; Bank AJ; Dengel DR
J Pediatr; 2004 Dec; 145(6):731-6. PubMed ID: 15580192
[TBL] [Abstract][Full Text] [Related]
16. Rapid effects of rosiglitazone treatment on endothelial function and inflammatory biomarkers.
Hetzel J; Balletshofer B; Rittig K; Walcher D; Kratzer W; Hombach V; Häring HU; Koenig W; Marx N
Arterioscler Thromb Vasc Biol; 2005 Sep; 25(9):1804-9. PubMed ID: 16002742
[TBL] [Abstract][Full Text] [Related]
17. Effect of rosiglitazone treatment on plaque inflammation and collagen content in nondiabetic patients: data from a randomized placebo-controlled trial.
Meisner F; Walcher D; Gizard F; Kapfer X; Huber R; Noak A; Sunder-Plassmann L; Bach H; Haug C; Bachem M; Stojakovic T; März W; Hombach V; Koenig W; Staels B; Marx N
Arterioscler Thromb Vasc Biol; 2006 Apr; 26(4):845-50. PubMed ID: 16410460
[TBL] [Abstract][Full Text] [Related]
18. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with metformin.
Derosa G; D'Angelo A; Ragonesi PD; Ciccarelli L; Piccinni MN; Pricolo F; Salvadeo SA; Montagna L; Gravina A; Ferrari I; Paniga S; Cicero AF
Intern Med J; 2007 Feb; 37(2):79-86. PubMed ID: 17229249
[TBL] [Abstract][Full Text] [Related]
19. Effects of peroxisome proliferator-activated receptor-gamma activation with pioglitazone on plasma adipokines in nondiabetic patients with either hypercholesterolemia or hypertension.
Barac A; Campia U; Matuskey LA; Lu L; Panza JA
Am J Cardiol; 2008 Apr; 101(7):980-5. PubMed ID: 18359318
[TBL] [Abstract][Full Text] [Related]
20. Rosiglitazone improves endothelial function and inflammation but not asymmetric dimethylarginine or oxidative stress in patients with type 2 diabetes mellitus.
Kelly AS; Thelen AM; Kaiser DR; Gonzalez-Campoy JM; Bank AJ
Vasc Med; 2007 Nov; 12(4):311-8. PubMed ID: 18048467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
